
What smart money is saying about Ion Beam Applications SA
1 fund in our archive has pitched Ion Beam Applications SA, most recently Paladin ONE in September 2026.
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation and energy switching while the gantry is rotating; Proteus ONE, a compact proton therapy system transforming cancer treatment; Proteus PLUS, a proton therapy solution for cancer centers; and dosimetry solutions that includes radiation therapy; medical imaging; and QUASAR that offers a portfolio of sophisticated phantoms supporting MR guided radiation therapy, motion management, surface guided radiation therapy, geometric distortion analysis, and machine targeting solutions. It also offers radio pharma solutions, including radioisotopes, cyclotrons, and radiochemistry, as well as other integrated and industrial solutions, and services. In addition, the company is involved in construction of proton therapy, and other accelerators equipment and installation services; and operation and maintenance services, as well as sales a license for intellectual property. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Get an email when a fund buys, sells or pitches it
Position history
Every position in Ion Beam Applications SA on record in the archive was reported in Q3 2026, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position
- HoldsPaladin ONESeptember 2026
“IBA: Further improved profitability and a hidden option called PanTera Ion Beam Applications (IBA) is another core position.”
Ion Beam Applications SA
Fund coverage · 1 thesis
- Paladin ONESeptember 2026
IBA is the world's leading proton therapy equipment and service provider, with a record 1.6 billion euro order backlog, a margin target of about 10 percent by 2028, and a 31 percent stake in PanTera, an actinium-225 producer that could be worth over 1 billion euros.
Read the full thesis
Read every full thesis on Ion Beam Applications SA
Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→